Li Siqi, Sang Baojun, Liu Jun, Liu Yuxuan, Xu Yanfeng, Sun Xiaorong, Yang Jigang
Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Ann Nucl Med. 2025 Apr;39(4):353-363. doi: 10.1007/s12149-024-02006-3. Epub 2024 Dec 15.
The study aimed to explore the role of fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide (F-OC) positron emission tomography/computed tomography (PET/CT) in neuroblastoma (NB) and compared it with Iodine-123 labeled metaiodobenzylguanidine (I-MIBG) scintigraphy with single photon emission computed tomography/computed tomography (SPECT/CT), as well as to investigate the feasibility of the modified Curie scoring system and International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) skeleton scoring system applied in F-OC PET/CT.
Patients with pathologically confirmed NB underwent I-MIBG scintigraphy with SPECT/CT and F-OC PET/CT according the standard imaging protocols. The interval between the two imaging techniques ranged from 0 to 22 days (median interval: 9 days). The number of lesions in modified Curie scoring system and SIOPEN skeleton scoring system applied on I-MIBG SPECT/CT and F-OC PET/CT was compared.
A total of 50 NB patients (male: female = 25:25) with a median age of 62-month-old were enrolled. I-MIBG and F-OC imaging were positive in 22 patients and negative in 27 patients. 1 patient had positive F-OC but negative I-MIBG results (p = 1.000). In lesion-based analysis, F-OC PET/CT revealed more positive lesions than I-MIBG scintigraphy with SPECT/CT (57 vs. 44, p < 0.001), regardless of bone/bone marrow lesions (43 vs. 37, p = 0.031) or soft tissue lesions (14 vs. 7, p = 0.016). The Curie scores of the two imaging techniques showed a significant difference (p = 0.047), whereas no statistic difference for SIOPEN scores (p = 0.688). The Curie and SIOPEN scores were significantly higher in patients with the presence of MYCN amplification or positive bone marrow puncture result (p < 0.05).
F-OC could be used in the evaluation of NB, and the modified Curie scoring system could be used to semi-quantify the disease extent of NB in F-OC PET/CT.
本研究旨在探讨氟-18-氟化铝-1,4,7-三氮杂环壬烷-1,4,7-三乙酸-奥曲肽（F-OC）正电子发射断层扫描/计算机断层扫描（PET/CT）在神经母细胞瘤（NB）中的作用，并将其与碘-123标记的间碘苄胍（I-MIBG）单光子发射计算机断层扫描/计算机断层扫描（SPECT/CT）闪烁显像进行比较，同时研究改良居里评分系统和欧洲儿科肿瘤学会神经母细胞瘤国际协会（SIOPEN）骨骼评分系统应用于F-OC PET/CT的可行性。
经病理确诊的NB患者按照标准成像方案接受I-MIBG SPECT/CT闪烁显像和F-OC PET/CT检查。两种成像技术之间的间隔时间为0至22天（中位间隔时间：9天）。比较I-MIBG SPECT/CT和F-OC PET/CT应用改良居里评分系统和SIOPEN骨骼评分系统时的病灶数量。
共纳入50例NB患者（男∶女 = 25∶25），中位年龄为62个月。I-MIBG和F-OC显像阳性22例，阴性27例。1例患者F-OC阳性但I-MIBG结果阴性（p = 1.000）。在基于病灶的分析中，F-OC PET/CT显示的阳性病灶比I-MIBG SPECT/CT闪烁显像更多（57个 vs. 44个，p < 0.001），无论骨/骨髓病灶（43个 vs. 37个，p = 0.031）还是软组织病灶（14个 vs. 7个，p = 0.016）。两种成像技术的居里评分显示出显著差异（p = 0.047），而SIOPEN评分无统计学差异（p = 0.688）。存在MYCN扩增或骨髓穿刺结果阳性的患者，其居里评分和SIOPEN评分显著更高（p < 0.05）。
F-OC可用于NB的评估，改良居里评分系统可用于对F-OC PET/CT中NB的疾病范围进行半定量分析。
